Reducing Ventricular Tachycardia Burden via Targeted Proton Irradiation

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Heart Rhythm https://doi.org/10.1016/j.hrthm.2026.04.021
Dr. Konstantinos C. Siontis et al.

Points

Researchers conducted a first-in-human study using highly targeted proton beam therapy to treat seven patients suffering from life-threatening ventricular tachycardia who failed to respond to traditional medical treatments.
The clinical findings demonstrated a significant seventy-nine percent reduction in heart rhythm episodes with the average frequency dropping from over seven events per month to just one point five.
This noninvasive procedure utilizes precise proton beams to eliminate the specific areas of heart tissue responsible for abnormal electrical signals while successfully protecting the surrounding healthy organs and tissue.
Follow-up data spanning two years indicated that the therapy was feasible and safe with no serious treatment-related side effects and stable heart function observed in the participating patients.
These encouraging results suggest that proton beam therapy could provide a vital new clinical option for advanced heart disease patients and warrants further investigation in larger prospective clinical trials.

Summary

This study evaluated the feasibility and clinical safety of using proton beam therapy for cardiac radioablation in patients with refractory ventricular tachycardia (VT). Given that patients with advanced heart disease often exhaust standard treatment options like catheter ablation and antiarrhythmic medications, the research sought to determine if highly targeted, noninvasive proton irradiation could effectively suppress abnormal electrical signals. The investigation involved seven patients with advanced heart failure who underwent a single session of proton therapy directed at the arrhythmogenic substrate.

The analysis revealed that proton beam therapy significantly reduced the frequency of life-threatening arrhythmias. Specifically, VT episodes decreased by 79%, falling from a baseline average of 7.2 episodes per month to 1.5 episodes per month following the procedure. During a follow-up period extending up to two years, key hemodynamic measures remained stable, and no serious treatment-related toxicities were identified. While some participants succumbed to complications of their underlying advanced heart disease or required transplantation, the therapy itself demonstrated high precision in targeting cardiac tissue while sparing healthy surrounding organs.

The findings suggest that proton-based cardiac radioablation is a viable, catheter-free alternative for patients with few remaining clinical options. Unlike conventional photon-based radiation, the physical properties of proton beams allow for a more rapid dose fall-off, potentially reducing long-term radiation exposure to non-target myocardium. These results support the expansion of this technique into larger prospective clinical trials to confirm its long-term efficacy and safety. Future research will focus on identifying the specific patient subgroups that derive the greatest benefit from this noninvasive therapeutic paradigm.

Link to the article: https://www.heartrhythmjournal.com/article/S1547-5271(26)02271-X/abstract

References

Siontis, K. C., Merrell, K. W., Deisher, A. J., Shumway, D. A., Rettmann, M. E., Kapa, S., Kowlgi, G. N., Asirvatham, S. J., Welch, E. M., Kruse, J., Foote, R. L., & Packer, D. L. (2026). Early feasibility study of catheter-free cardiac radioablation with proton beams for refractory ventricular tachycardia. Heart Rhythm, S154752712602271X. https://doi.org/10.1016/j.hrthm.2026.04.021